ADMA Biologics Statistics
Total Valuation
ADMA Biologics has a market cap or net worth of $2.20 billion. The enterprise value is $2.20 billion.
| Market Cap | 2.20B |
| Enterprise Value | 2.20B |
Important Dates
The next estimated earnings date is Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ADMA Biologics has 238.16 million shares outstanding. The number of shares has increased by 5.07% in one year.
| Current Share Class | 238.16M |
| Shares Outstanding | 238.16M |
| Shares Change (YoY) | +5.07% |
| Shares Change (QoQ) | -0.33% |
| Owned by Insiders (%) | 2.05% |
| Owned by Institutions (%) | 93.96% |
| Float | 233.17M |
Valuation Ratios
The trailing PE ratio is 15.42 and the forward PE ratio is 9.69.
| PE Ratio | 15.42 |
| Forward PE | 9.69 |
| PS Ratio | 4.32 |
| Forward PS | 3.39 |
| PB Ratio | 4.61 |
| P/TBV Ratio | 4.66 |
| P/FCF Ratio | 79.18 |
| P/OCF Ratio | 43.71 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.00, with an EV/FCF ratio of 78.91.
| EV / Earnings | 14.94 |
| EV / Sales | 4.30 |
| EV / EBITDA | 11.00 |
| EV / EBIT | 11.47 |
| EV / FCF | 78.91 |
Financial Position
The company has a current ratio of 6.71, with a Debt / Equity ratio of 0.17.
| Current Ratio | 6.71 |
| Quick Ratio | 3.54 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 0.40 |
| Debt / FCF | 2.87 |
| Interest Coverage | 26.93 |
Financial Efficiency
Return on equity (ROE) is 35.56% and return on invested capital (ROIC) is 33.39%.
| Return on Equity (ROE) | 35.56% |
| Return on Assets (ROA) | 21.50% |
| Return on Invested Capital (ROIC) | 33.39% |
| Return on Capital Employed (ROCE) | 34.51% |
| Weighted Average Cost of Capital (WACC) | 7.50% |
| Revenue Per Employee | $788,521 |
| Profits Per Employee | $227,094 |
| Employee Count | 647 |
| Asset Turnover | 0.92 |
| Inventory Turnover | 1.15 |
Taxes
In the past 12 months, ADMA Biologics has paid $35.73 million in taxes.
| Income Tax | 35.73M |
| Effective Tax Rate | 19.56% |
Stock Price Statistics
The stock price has decreased by -53.05% in the last 52 weeks. The beta is 0.59, so ADMA Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -53.05% |
| 50-Day Moving Average | 15.63 |
| 200-Day Moving Average | 16.84 |
| Relative Strength Index (RSI) | 24.81 |
| Average Volume (20 Days) | 9,001,333 |
Short Selling Information
The latest short interest is 25.83 million, so 10.84% of the outstanding shares have been sold short.
| Short Interest | 25.83M |
| Short Previous Month | 19.14M |
| Short % of Shares Out | 10.84% |
| Short % of Float | 11.08% |
| Short Ratio (days to cover) | 7.16 |
Income Statement
In the last 12 months, ADMA Biologics had revenue of $510.17 million and earned $146.93 million in profits. Earnings per share was $0.60.
| Revenue | 510.17M |
| Gross Profit | 292.77M |
| Operating Income | 191.44M |
| Pretax Income | 182.66M |
| Net Income | 146.93M |
| EBITDA | 199.54M |
| EBIT | 191.44M |
| Earnings Per Share (EPS) | $0.60 |
Balance Sheet
The company has $87.63 million in cash and $79.89 million in debt, with a net cash position of $7.75 million or $0.03 per share.
| Cash & Cash Equivalents | 87.63M |
| Total Debt | 79.89M |
| Net Cash | 7.75M |
| Net Cash Per Share | $0.03 |
| Equity (Book Value) | 477.32M |
| Book Value Per Share | 2.01 |
| Working Capital | 396.97M |
Cash Flow
In the last 12 months, operating cash flow was $50.40 million and capital expenditures -$22.58 million, giving a free cash flow of $27.82 million.
| Operating Cash Flow | 50.40M |
| Capital Expenditures | -22.58M |
| Depreciation & Amortization | 8.10M |
| Net Borrowing | -938,000 |
| Free Cash Flow | 27.82M |
| FCF Per Share | $0.12 |
Margins
Gross margin is 57.39%, with operating and profit margins of 37.53% and 28.80%.
| Gross Margin | 57.39% |
| Operating Margin | 37.53% |
| Pretax Margin | 35.80% |
| Profit Margin | 28.80% |
| EBITDA Margin | 39.11% |
| EBIT Margin | 37.53% |
| FCF Margin | 5.45% |
Dividends & Yields
ADMA Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.07% |
| Shareholder Yield | -5.07% |
| Earnings Yield | 6.67% |
| FCF Yield | 1.26% |
Analyst Forecast
The average price target for ADMA Biologics is $32.00, which is 245.95% higher than the current price. The consensus rating is "Buy".
| Price Target | $32.00 |
| Price Target Difference | 245.95% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 20.35% |
| EPS Growth Forecast (5Y) | 35.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ADMA Biologics has an Altman Z-Score of 19.64 and a Piotroski F-Score of 6.
| Altman Z-Score | 19.64 |
| Piotroski F-Score | 6 |